Posts Tagged ‘Popper and company’



Welcoming Stephanie Kreml, M.D. as Newest Team Member

April 3rd, 2013
Posted by

I’m pleased to announce that Stephanie Kreml, M.D. has returned to Popper and Company, joining our core team of life science advisors as Principal.
 
Like all of our team members, Stephanie is committed to delivering perspective, value, and high-quality, hands-on service to clients across the life sciences spectrum.  As a practicing physician with an engineering background, Stephanie brings a unique multi-disciplinary perspective to helping life sciences companies address diverse healthcare issues.  She is an excellent addition to our existing team of experts whose operational backgrounds span clinical, technology, marketing and finance in a variety of capacities in the diagnostics, medical device, pharmaceuticals and digital health industries.
  Read the rest of this entry »

Tags: , , , , ,
Posted in Our News | No Comments »





Welcoming Head of Digital Health Strategy Paul Sonnier as Newest Team Member

March 13th, 2012
Posted by

I’m delighted to announce that Paul Sonnier, formerly a strategic advisor to Popper and Company, has joined our core team as Head of Digital Health Strategy.
 
Our core team provides diversity and expertise to resolve problems and create strategies in the health arena for our life science clients. Paul, who has recently been described as a catalyst in the wireless and mobile health field, brings his familiarity, insights and experience to our existing team of experts whose operational backgrounds span clinical, technology, marketing and finance in a variety of capacities in the diagnostics, medical device and pharmaceutical industries.
  Read the rest of this entry »

Tags: , , , , , ,
Posted in Our News | 2 Comments »





Companion Diagnostics: More Targeted Medicine on the Horizon

September 12th, 2011
Posted by

It’s increasingly clear to anyone who deals with human health – from the bench biologist to the clinical oncologist – that humans are a heterogeneous species. As a result, a drug that works well in one individual may not work at all in another. Thus, the field of targeted (or personalized) medicine came about so doctors could optimize patient care through the use of genetic and biomarker testing. Such tests help identify patients who are (or who are not) most likely to respond to a given therapy. The field is often promoted as a way to get the “right drug to the right patient at the right dose.”
 
Correct dosing is critical because about 25 percent of all outpatient prescription drugs in the U.S. are taken by patients with genetic variations (specifically, polymorphisms) that affect absorption, metabolism or excretion of those drugs. Again, at risk of stating the obvious, human beings are heterogeneous.

  Read the rest of this entry »

Tags: , , , , , ,
Posted in Our Views | No Comments »





Another Distribution Giant Sees Future for Patient Informatics

September 8th, 2011
Posted by

Following McKesson’s bold move with the acquisition of US Oncology last December, another distribution giant has entered the arena of helping oncologists manage patient care. AmerisourceBergen Corporation recently announced its purchase of IntrinsiQ, LLC—a provider of informatics products directly involved in assisting oncologists with clinical dosing decisions.
 
We’re uncertain as to whether AmerisourceBergen’s expansion in this arena shows an aggressive push for new market traction, a creative way to garner physicians’ mindshare or whether they’re simply betting on the growing informatics market. It does, however, seem  likely that a distributor would want to add value to its “middleman” role. And this signals one thing that is for sure: Distributors are getting closer to physicians on a core level—right down to how they prescribe vital medications.
 
Why is this happening? AmerisourceBergen stated its reasoning in a recent announcement on Drugs.com: “Oncologists need strategic partners that can capture actionable intelligence…” In short, physicians face an increasingly complex world of decisions every day, and information technology may be the only available edge when treatment options are many and time is critical.
  Read the rest of this entry »

Tags: , , , , , ,
Posted in Our Views | No Comments »





Why Should the Life Science Industry Care About Davos?

January 27th, 2011
Posted by

CNN’s Dr. Sanjay Gupta went on air yesterday to explain why he, as a physician, is attending the World Economic Forum 2011 Annual Meeting taking place right now in Davos, Switzerland.
 
To paraphrase Dr. Gupta, health – and its impact on world economic development – is a big topic at the Davos meeting. He noted, “In terms of health care delivery, there is growing recognition by the forum that existing models simply aren’t sustainable in developed countries, and there simply isn’t enough access in the developing world. Some of that is old news, but the topics at Davos were chosen to address solutions in these areas. For example, I will be moderating panel discussions on topics ranging from personalized medicine to combating chronic disease.”
 
Because of the overarching health-related themes being discussed at Davos, the life science industry – particularly companies seeking to develop diagnostics and devices to address human illness – should focus on what’s taking place at Davos, as well. Following are a few of the critical themes being discussed that draw my attention:
  Read the rest of this entry »

Tags: , , , , , , , , ,
Posted in Our News | No Comments »





Finding the Piece of Hay in the Haystack

December 20th, 2010
Posted by

I once read a blog about imprecise metaphors in which the author wrote that it’s easy to find a needle in a haystack, but immensely difficult to find a particular piece of hay in that haystack. Needle: Obvious. One piece of hay versus another: Not so obvious.
 
In these mercurial times in the life sciences and technology industries, attempting to identify information that is significant and useful can be as overwhelming as trying to find that one piece of hay.
 
Every day we encounter immense amounts of data and then we must pause for a moment to select what is essential and applicable to the topic at hand.
 
At Popper and Company, we keep a sharp eye toward emerging technologies whether it be in the development of point-of-care tests, regulatory and reimbursement issues, personalized medicine, the global expansion of mobile medicine or other areas of interest.
  Read the rest of this entry »

Tags: , , , ,
Posted in Our Views | No Comments »